Abraxane News and Research

RSS

The U.S. Food and Drug Administration approved Abraxane for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in January 2005 for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.

Results from Celgene’s ABRAXANE plus gemcitabine clinical study on resectable pancreatic cancer

Celgene International Sàrl, a subsidiary of Celgene Corporation today announced results from a study of ABRAXANE(paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine in patients with resectable pancreatic cancer.

5 Jun 2012

BioTrends tracks uptake of Yervoy and Zelboraf for advanced melanoma

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, has released findings from the second wave of its LaunchTrends® Yervoy and Zelboraf report, in which 103 U.S.-based medical oncologists were surveyed about their current and expected treatment patterns in advanced melanoma.

11 May 2012

Study provides guidelines on how to combine antiangiogenic drugs with nanotherapeutics

Combining two strategies designed to improve the results of cancer treatment - antiangiogenesis drugs and nanomedicines - may only be successful if the smallest nanomedicines are used. A new study from Massachusetts General Hospital (MGH) researchers, appearing in Nature Nanotechnology, finds that normalizing blood vessels within tumors, which improves the delivery of standard chemotherapy drugs, can block the delivery of larger nanotherapy molecules.

10 Apr 2012

Study identifies how chemo drug combination kills pancreatic cancer cells

Cancer Research UK scientists have discovered how a combination of two chemotherapy drugs - already showing promise in clinical trials - destroys pancreatic cancer cells, according to research published in Cancer Discovery.

29 Feb 2012

Researchers test nanoscale carbon clusters for cancer chemotherapy

A mixture of current drugs and carbon nanoparticles shows potential to enhance treatment for head-and-neck cancers, especially when combined with radiation therapy, according to new research by Rice University and the University of Texas MD Anderson Cancer Center.

16 Feb 2012

Elan fourth quarter total revenue increases 18% to $271.0 million

Elan Corporation, plc today reported its fourth quarter and full-year 2011 financial results.

8 Feb 2012

Survey reveals high interest in Xalkori among medical oncologists

According to survey results gathered from 80 Medical Oncologists in the United States there is an extreme interest in Xalkori, with 75% of respondents stating a high interest in prescribing the product, virtually no physicians stating they have low interest in prescribing the therapy.

13 Jan 2012

Scottsdale resident donates $1 million to TGen pancreatic cancer initiative

A son's passion to find a cure for the cancer that claimed the life of his mother has led to a new series of clinical trials under a Translational Genomics Research Institute (TGen) initiative to find a cure for pancreatic cancer.

2 Dec 2011

Chloroquine-chemotherapy combination holds potential for metastatic breast cancer treatment

An anti-malaria drug used for more than 60 years is now being studied for use in breast cancer patients whose disease has not responded to traditional chemotherapy treatment.

18 Nov 2011

Elan's third quarter total revenue increases 17% to $328.5 million

Elan Corporation, plc today reported its third quarter and first nine months 2011 financial results.

27 Oct 2011

JCO publishes data from Celgene's ABRAXANE Phase II combination trial on pancreatic cancer

Celgene International Sàrl today announced that results from a clinical study of ABRAXANE in combination with gemcitabine in 67 patients with previously untreated advanced pancreatic cancer were published in an online article by the Journal of Clinical Oncology ahead of print.

7 Oct 2011

Celgene reports second quarter total revenue of $1.18 billion

Celgene Corporation announced non-GAAP net income of $417 million, or non-GAAP diluted earnings per share of $0.89, for the quarter ended June 30, 2011. Non-GAAP net income for the second quarter of 2010 was $323 million, or non-GAAP diluted earnings per share of $0.69.

28 Jul 2011

NYU Cancer Institute scientists present new research findings at ASCO 2011

Experts from The Cancer Institute, an NCI-designated cancer center, at NYU Langone Medical Center presented new research findings at the 47th American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago, IL.

8 Jun 2011

ABRAXANE and bevacizumab clinical studies on unresectable melanoma presented at ASCO 2011

Celgene International Sàrl today announced that results from two investigator initiated studies including ABRAXANE, and bevacizumab in unresectable melanoma were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Celgene announces ABRAXANE plus gemcitabine, bevacizumab phase II trial data on breast cancer

Celgene International Sàrl today announced that results from an investigator-initiated phase II study of ABRAXANE, gemcitabine and bevacizumab as first-line treatment in metastatic breast cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, IL.

7 Jun 2011

Celgene non-GAAP total revenue increases 40% to $1.11 billion

Celgene Corporation: “The results for the quarter were outstanding and they reflect the ongoing momentum that Celgene is creating as we leverage our business model and position our Company for long-term success”.

28 Apr 2011

Celgene, Elan enter settlement and license agreement for ABRAXANE

Elan Corporation plc and Celgene Corporation, today announced that Elan subsidiary Elan PharmaInternational Limited has entered into a settlement and license agreement with Celgene Corporation resolving the patent infringement litigation involving ABRAXANE.

24 Feb 2011

Physicians reaction to FDA decision to rescind breast cancer indication from Avastin

Sermo, the world's largest online community for physicians, announced the publication of a free Sermo Report about how physicians are reacting to the FDA decision to rescind the indication for Avastin (bevacizumab) in the treatment of breast cancer.

5 Feb 2011

Celgene third quarter non-GAAP total revenue increases 31% to $908 million

Celgene Corporation announced non-GAAP net income of $349.9 million, or non-GAAP diluted earnings per share of $0.75 for the quarter ended September 30, 2010.

28 Oct 2010

Celgene acquires Abraxis BioScience

Celgene Corporation today announced it has completed its acquisition of Abraxis BioScience, Inc. For each share of Abraxis common stock, Abraxis shareholders will receive (i) $58.00 in cash (ii) 0.2617 shares of Celgene common stock, and (iii) one tradeable Contingent Value Right (CVR), which entitles its holder to receive a pro rata share of potential payments for future regulatory milestones and commercial royalties.

18 Oct 2010